A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma (Q35848351)
Jump to navigation
Jump to search
scientific article published on 7 July 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma |
scientific article published on 7 July 2005 |
Statements
1 reference
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma (English)
1 reference
Auayporn Nademanee
1 reference
Stephen Forman
1 reference
Arturo Molina
1 reference
Henry Fung
1 reference
David Smith
1 reference
Andy Dagis
1 reference
Cheuk Kwok
1 reference
Dave Yamauchi
1 reference
Anne-Line Anderson
1 reference
Peter Falk
1 reference
Amrita Krishnan
1 reference
Mark Kirschbaum
1 reference
Neil Kogut
1 reference
Ryotaro Nakamura
1 reference
Margaret O'donnell
1 reference
Pablo Parker
1 reference
Leslie Popplewell
1 reference
Vinod Pullarkat
1 reference
Roberto Rodriguez
1 reference
Firoozeh Sahebi
1 reference
Eileen Smith
1 reference
David Snyder
1 reference
Anthony Stein
1 reference
Ricardo Spielberger
1 reference
Jasmine Zain
1 reference
Christine White
1 reference
Andrew Raubitschek
1 reference
7 July 2005
1 reference
1 reference
2896-2902
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference